Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 2 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 12318362

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  2. US 12318401

    Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

    The Regents of the University of California · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  3. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  4. US 12318413

    Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

    The Board of Regents of the University of Texas System · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  5. US 12311030

    Antibody-sting agonist conjugates and their use in immunotherapy

    The Board of Regents of the University of Texas System · Granted May 27, 2025 · Expires May 22, 2045

    granted
  6. US 12310996

    Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

    The Board of Regents of the University of Texas System · Granted May 27, 2025 · Expires May 22, 2045

    granted
  7. US 12303551

    Cellular immunotherapy compositions and uses thereof

    Cero Therapeutics Holdings, Inc. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  8. US 12297447

    Gene therapy for juvenile Batten disease

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted May 13, 2025 · Expires May 8, 2045

    granted
  9. US 12297509

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted May 13, 2025 · Expires May 8, 2045

    granted
  10. US 12285496

    Gene therapy for haploinsufficiency

    The Regents of the University of California · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  11. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  12. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  13. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  14. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  15. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  16. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  17. US 12233103

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  18. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  19. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  20. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  21. US 12228582

    Method and apparatus for testing near infrared-photoimmunotherapy treatment

    The United States of America as Represented By The Secretary of the Department of Health and Human · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  22. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  23. US 12220389

    Combination therapy for the treatment of tinnitus and other medical conditions

    The Regents of the University of California · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  24. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted